Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers

(MedPage Today) -- MADRID -- Treatment with an investigational TROP2-directed antibody-drug conjugate (ADC) significantly improved progression-free survival (PFS) in patients with previously treated metastatic breast cancer and non-small cell...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news